After finishing at $5.39 in the prior trading day, Fate Therapeutics Inc. (NASDAQ: FATE) closed at $5.48, up 1.67%. In other words, the price has increased by $+0.09 from its previous closing price. On the day, 2968198 shares were traded. FATE stock price reached its highest trading level at $5.50 during the session, while it also had its lowest trading level at $5.26.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
Our goal is to gain a better understanding of FATE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.40 and its Current Ratio is at 4.40. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on January 24, 2023, Downgraded its rating to Neutral and sets its target price to $7 from $115 previously.
On January 06, 2023, Wedbush Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $42 to $7.
Truist Downgraded its Buy to Hold on January 06, 2023, whereas the target price for the stock was revised from $46 to $7.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 13 when MENDLEIN JOHN bought 36,631 shares for $5.43 per share. The transaction valued at 198,906 led to the insider holds 282,770 shares of the business.
MENDLEIN JOHN bought 88,048 shares of FATE for $499,232 on Jan 11. The Director now owns 246,139 shares after completing the transaction at $5.67 per share. On Jan 10, another insider, Wolchko J Scott, who serves as the President and CEO of the company, sold 45,907 shares for $5.24 each. As a result, the insider received 240,553 and left with 385,639 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.12 while its Price-to-Book (P/B) ratio in mrq is 1.10.
Stock Price History:
Over the past 52 weeks, FATE has reached a high of $43.12, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 6.27, while the 200-Day Moving Average is calculated to be 19.42.
Shares Statistics:
The stock has traded on average 3.94M shares per day over the past 3-months and 2.81M shares per day over the last 10 days, according to various share statistics. A total of 97.22M shares are outstanding, with a floating share count of 95.67M. Shares short for FATE as of Jan 30, 2023 were 16.28M with a Short Ratio of 18.66M, compared to 22.33M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 16.76% and a Short% of Float of 22.40%.
Earnings Estimates
Its stock is currently analyzed by 24 different market analysts. On average, analysts expect EPS of -$0.86 for the current quarter, with a high estimate of -$0.56 and a low estimate of -$1.12, while EPS last year was -$0.72. The consensus estimate for the next quarter is -$0.68, with high estimates of -$0.38 and low estimates of -$1.15.
Analysts are recommending an EPS of between -$2.89 and -$3.66 for the fiscal current year, implying an average EPS of -$3.21. EPS for the following year is -$2.09, with 24 analysts recommending between -$0.88 and -$3.21.
Revenue Estimates
19 analysts predict $16.72M in revenue for the current quarter. It ranges from a high estimate of $24.98M to a low estimate of $1.5M. As of the current estimate, Fate Therapeutics Inc.’s year-ago sales were $17.07M, an estimated decrease of -2.00% from the year-ago figure.
A total of 24 analysts have provided revenue estimates for FATE’s current fiscal year. The highest revenue estimate was $101.94M, while the lowest revenue estimate was $48.75M, resulting in an average revenue estimate of $69.11M. In the same quarter a year ago, actual revenue was $55.85M, up 23.80% from the average estimate.
